This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.
What's in Store for Varian Medical (VAR) in Q1 Earnings?
by Zacks Equity Research
Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.
Stryker (SYK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.
PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.
What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.
Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.
Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance
by Zacks Equity Research
Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.
Medical Products' Oct 24 Earnings Roster: BAX, CERN & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
What's in the Offing for Baxter's (BAX) Earnings in Q3?
by Zacks Equity Research
Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.
Baxter International (BAX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HRC or BAX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRC vs. BAX: Which Stock Is the Better Value Option?
Stryker Gains From Flagship Mako and Broad Product Spectrum
by Zacks Equity Research
Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.
Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test
by Zacks Equity Research
The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.
Haemonetics Grows on Strong Plasma, Hemostasis Management
by Zacks Equity Research
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
Here's Why You Should Hold on to Wright Medical (WMGI) Stock
by Zacks Equity Research
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
by Zacks Equity Research
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
Here's Why You Should Hold on to Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Fresenius Medical Launches 4008A Dialysis Machine in China
by Zacks Equity Research
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
Align Technology Inks Distribution Deal With Zimmer Biomet
by Zacks Equity Research
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
PRA Health Simplifies Treatment Decisions With Metys Launch
by Zacks Equity Research
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.